Keratinocytes drive melanoma invasion in a reconstructed skin model

Melanoma Research

Volumn 20, Issue 5, 2010, Pages 372-380

  Van Kilsdonk, Jeroen W J ^a,b   Bergers, Mieke ^b   Van Kempen, Léon C L T ^b   Schalkwijk, Joost ^b   Swart, Guido W M ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

melanoma; migration; nvasion; proteases; reconstructed skin; skin models

Indexed keywords

GELATINASE B;

ARTICLE; BASEMENT MEMBRANE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CELL STRUCTURE; DERMOEPIDERMAL JUNCTION; ENZYME ACTIVATION; EPIDERMIS; HISTOLOGY; HUMAN; HUMAN TISSUE; KERATINOCYTE; MELANOMA; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION;

EID: 77957580449     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32833d8d70     Document Type: Article

References (35)

1. Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 2005;10:153-163.
2. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006;355:51-65.
3. Arribas J, Borroto A. Protein ectodomain shedding. Chem Rev 2002;102:4627-4638.
4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
5. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002;70:561-573.
6. Hofmann UB, Houben R, Brocker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005;87:307-314.
7. Arribas J, Bech-Serra JJ, Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev 2006;25:57-68.
8. Tousseyn T, Jorissen E, Reiss K, Hartmann D. (Make) stick and cut loose-disintegrin metalloproteases in development and disease. Birth Defects Res C Embryo Today 2006;78:24-46.
9. Dewhurst LO, Gee JW, Rennie IG, MacNeil S. Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. Br J Cancer 1997;75:860-868.
10. Murata J, Ayukawa K, Ogasawara M, Fujii H, Saiki I. Alpha-melanocyte- stimulating hormone blocks invasion of reconstituted basement membrane (Matrigel) by murine B16 melanoma cells. Invasion Metastasis 1997;17:82-93.
11. Seftor EA, Brown KM, Chin L, Kirschmann DA, Wheaton WW, Protopopov A, et al. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Cancer Res 2005;65:10164-10169.
12. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-1144.
13. Meier F, Nesbit M, Hsu MY, Martin B, Van Belle P, Elder DE, et al. Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol 2000;156:193-200.
14. Eves P, Layton C, Hedley S, Dawson RA, Wagner M, Morandini R, et al. Characterization of an in vitro model of human melanoma invasion based on reconstructed human skin. Br J Dermatol 2000;142:210-222.
15. Dekker SK, van Doorn R, Kempenaar J, Gruis NA, Vermeer BJ, Ponec M. Skin equivalent: an attractive model to evaluate early melanoma metastasis. Melanoma Res 2000;10:127-140.
16. Eves P, Katerinaki E, Simpson C, Layton C, Dawson R, Evans G, et al. Melanoma invasion in reconstructed human skin is influenced by skin cells-investigation of the role of proteolytic enzymes. Clin Exp Metastasis 2003;20:685-700. (Pubitemid 38019271)
17. Degen WG, van Kempen LC, Gijzen EG, van Groningen JJ, van Kooyk Y, Bloemers HP, et al. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol 1998;152:805-813.
18. Van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ, Garbe C, Weidle UH, et al. Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol 2004;122:1293-1301.
19. Van Kilsdonk JW, Wilting RH, Bergers M, van Muijen GN, Schalkwijk J, van Kempen LC, et al. Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res 2008;68:3671-3679.
20. Van den Born J, Gunnarsson K, Bakker MA, Kjellen L, Kusche-Gullberg M, Maccarana M, et al. Presence of N-unsubstituted glucosamine units in native heparan sulfate revealed by a monoclonal antibody. J Biol Chem 1995;270:31303-31309.
21. Weterman MA, van Muijen GN, Bloemers HP, Ruiter DJ. Expression of calcyclin in human melanocytic lesions. Cancer Res 1993;53:6061-6066.
22. Lunter PC, van Kilsdonk JW, van Beek H, Cornelissen IM, Bergers M, Willems PH, et al. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 2005;65:8801-8808.
23. Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 2002;3:35-43.
24. Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 2005;18:150-159.
25. Han YP, Nien YD, Garner WL. Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase. J Biol Chem 2002;277:27319-27327.
26. Van den Oord JJ, Paemen L, Opdenakker G, Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997;151:665-670.
27. Van Kempen LC, Rijntjes J, Mamor-Cornelissen I, Vincent-Naulleau S, Gerritsen MJ, Ruiter DJ, et al. Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. Int J Cancer 2008;122:1019-1029.
28. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744.
29. Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 1999;17:177-181.
30. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2:289-300.
31. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-1051.
32. Tang A, Eller MS, Hara M, Yaar M, Hirohashi S, Gilchrest BA. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J Cell Sci 1994;107:983-992.
33. Hsu MY, Wheelock MJ, Johnson KR, Herlyn M. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1996;1:188-194.
34. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-490.
35. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001;193: F23-F26.